DDInter1615 DDInter1376
Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut following chemotherapy administration. Neurokinin-1 is also known as Tachykinin Receptor 1 (TACR1), Neurokinin 1 Receptor (NK1R), and Substance P Receptor (SPR). By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Rolapitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Rolapitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dextromethorphan
Rolapitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Rolapitant {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Rolapitant {u} may lead to a major life threatening interaction when taken with {v} Betrixaban
Rolapitant may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan
Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Rolapitant may lead to a major life threatening interaction when taken with Enzalutamide
Rolapitant may lead to a major life threatening interaction when taken with Betrixaban